IIM Series: ASMS Screening of the GLP1 Receptor with Can Ozbal, PhD and Maryna Löwe, PhD

Intelligent Infusions Masterclass on ASMS small molecule screening and binding studies of the GLP1 receptor. Key Takeaways: ◾ The NativeMP™ platform facilitates investigation of membrane proteins by effectively solubilizing and stabilizing target constructs. ◾ Affinity selection mass spectrometry (ASMS) is a powerful high-throughput screening technique used to identify small molecules that form non-covalent bonds with a target of interest. ◾ By leveraging NativeMP™ and a customized ASMS workflow, Cube Biotech and Momentum Biotechnologies successfully identified multiple small-molecule binders of the GLP1 receptor (GLP1R), an important target in the treatment of type 2 diabetes and obesity. The Speakers: ◾ Maryna is a medical biotechnologist with a PhD in biochemistry and experience in drug discovery and development. She has a strong background in membrane protein research and is one of our project managers at Cube Biotech. ◾ Can received his PhD in Toxicology from MIT before going on to develop and commercialize the RapidFire high-throughput mass spectrometry platform as part of the BioTrove team. He later helped spin out the RapidFire technology to create Biocius Life Sciences, staying on after its acquisition by Agilent in 2011. In 2014, Can founded Momentum Biotechnologies (f/k/a PureHoney Technologies), a CRO specializing in mass spectrometry-based screening and proteomics for drug discovery. Can has extensive expertise in technology development and commercialization, early drug discovery, analytical chemistry, and bioanalysis.